

# Index

---

- $\alpha$ -adrenoreceptors, 11
- $\beta$ -adrenoreceptors, 11
- 12-lead ECG, 81, 83, 94, 96, 102, 126, 140, 173, 180, 188, 199, 252
  - documentation, 96
  - electrodes, attaching, 96
    - limb leads, 96
    - precordial leads, 96
  - equipment preparation, 94–5
  - interpretation, 96
  - patient preparation, 95
    - information and consent, 95
    - patient privacy, 95
    - positioning, 95
    - skin preparation, 95
  - quality, 96
  - ST segment, 173
    - depression, 173
    - elevation, 173
- 3D echo, roles of, 125
- ABCDE approach, 251, 283
- abdominal obesity, 43, 286
- abnormal automaticity, 224
- abnormal breath sounds, 78
- 'absolute' risk, 40
- accelerated ventricular rhythm (AVR), 238
- acetylcholine, 9
- activated clotting time, 122
- activated coagulation time, 112
- activated partial thromboplastin time (aPTT), 112, 119, 212
- acute clinical deterioration, 245
- acute coronary syndromes (ACSs), 28, 55, 59, 61, 109, 112, 118, 157, 162, 168, 179, 185, 260
  - adjunct pharmacological agents in, 204
    - aldosterone receptor blockers, 216
    - angiotensin-converting enzyme inhibitors, 215
    - angiotensin receptor blockers, 216
    - anticoagulant therapy, 209–15
    - anti-ischaemic therapies, 205–9
    - antiplatelet therapy, 209–15
  - pathogenesis, 161, 162
    - atherosclerosis, 162
    - endothelial dysfunction, 162
    - inflammation, 163
    - plaque disruption, 162–3
    - thrombosis, 164
    - vasoconstriction, 164
  - presentations, 167, 168
    - 12-lead electrocardiogram, 173
    - AMI, 169
    - angina pectoris, 167–8
    - atypical presentations, 172
    - cardiac markers, 174
    - clinical assessment, 174–5
    - clinical classifications, 169
    - clinical history, 170–72
    - global trends, 170
    - physical examinations, 172–3
    - risk stratification, 174–5
    - stable angina, 168
    - triage nurse guidelines, 175
    - unstable angina pectoris, 169
  - risk stratification in, 178, 179
    - chest pain units (CPUs), 182–3
    - guidelines, 180–81
    - risk scores, 181–2

- acute heart failure (AHF), 109, 257–8  
causes and precipitating factors for, 259  
chronic heart failure, managing, 266  
definition, 257  
diagnosis, establishing, 258–60  
clinical features, 258–60  
investigations and monitoring in, 260–61  
dignity, communication and preventing complications, 265–6  
management specifics, 261  
oxygenation, 261–2  
pharmacotherapy, 262–3  
vasodilators, 263–4  
refractory AHF, 264  
cardiac resynchronisation therapy, 265  
intra-aortic balloon pump, 264  
ventricular assist devices, 264–5
- acute myocardial infarction (AMI), 61, 92, 138, 161, 163, 169, 171, 206, 212, 215
- adenosine, 129, 237, 240
- 'advanced directive', 155–6, 252–3
- advanced life support (ALS), 146, 244, 247, 248, 249, 250–51, 258
- advancing age, 42
- afterload, definition of, 7
- ajmaline, 142
- alcohol consumption, 34
- aldosterone, 12
- aldosterone receptor blockers, 216
- alpha-glucosidase inhibitors meglitinides, 32
- ambulance response, 187
- ambulatory ECG, 103
- American College of Cardiology (ACC), 133, 168
- American College of Physicians (ACP), 168
- American Heart Association (AHA), 133, 168, 274
- American Society of Internal Medicine (ASIM), 168
- amiodarone, 236, 237, 238, 240
- anaemia, 112
- angiography, 181
- angiotensin I, 12, 215
- angiotensin II, 12, 30, 215, 216
- angiotensin inhibitors, 290
- angiotensin-converting enzyme (ACE) inhibitors, 30, 141, 215, 289–90  
in acute coronary syndrome (ACS), 215  
in nursing management, 215
- angiotensin receptor blockers (ARBs), 216, 290
- 'angle of Louis', 96
- anterior cardiac veins, 24
- anticoagulant therapy, 209–10, 214  
low-molecular-weight heparins (LMWH), 212–13  
platelet GP IIb/IIIa receptor antagonists, 213, 215  
unfractionated heparin (UFH), 212
- anticoagulants, 212  
antiplatelet agents, 289
- antidiuretic hormone (ADH), 11
- antihistamines, 142
- anti-ischaemic therapies, 205, 207–8  
beta-adrenoceptor antagonists, 206  
calcium antagonists, 209  
nitrate therapy, 205–6
- antiplatelet therapy, 210–11  
aspirin, 210, 211  
clopidogrel, 210, 211–12
- antipsychotics, 142
- aortic bodies, 11
- apex beat, 70, 71
- arginine vasopressin (AVP), 12
- arrhythmia, 125, 140, 142, 222, 260  
asystole, 238–9  
basic electrophysiology, 223  
cardiac monitoring, 225  
generations, mechanisms of, 223–4  
monitoring, 103, 104  
rhythm determination, 227  
asymptomatic approach, 227  
bradyarrhythmia, 227  
escape beats, 232  
heart block, 227, 230–32  
idioventricular rhythm (IVR), 232  
junctional rhythm, 232  
rhythm interpretation, 225–7
- tachycardias, 232  
atrial fibrillation, 234, 236  
atrial flutter, 236–7  
sinus tachycardia, 232–3  
supraventricular tachycardia (SVT), 233–4, 235  
ventricular fibrillation, 238  
ventricular tachycardia (VT), 237–8
- treatment  
bradyarrhythmias, 239–40  
tachyarrhythmias, 240–41
- arrhythmogenic right ventricular cardiomyopathy (ARVC), 139, 141
- arrhythmogenic right ventricular dysplasia, 141
- arterial blood gas (ABG) analysis, 260–61
- arterioles, 24
- arteriovenous fistula, 123
- aspirin, 210, 211, 289
- ASSIGN, 41
- asystole, 146, 238–9
- atherosclerosis, 162
- atherosclerotic plaque, 162, 163, 164
- atrial conduction, 18
- atrial fibrillation (AF), 234, 235, 236
- atrial flutter, 235, 236–7
- atrial kick, 5
- atrial natriuretic peptide (ANP), 11, 113
- atrial systole, 3–5
- atrioventricular dissociation, 232
- atropine, 239
- 'augmented limb leads', 83, 84
- auscultatory method, 73
- Australia, CVD in, 43

- automated blood pressure measurement devices, 73  
 automated external defibrillator (AED), 145, 149, 250  
   factors affecting defibrillation  
     pad and skin, contact between, 149  
     pad position, 150  
     transthoracic impedance, 149  
 automaticity, 16, 224  
 autorhythmic cells, 15, 16  
 autosomal dominant syndromes, 142  
 autosomal recessive syndrome, 142  
 'axes', 124  
 axis determination, 85  
 axis deviation, common causes of, 85
- B-type natriuretic peptide (BNP), 12, 113, 114, 261  
 baroreceptors, 10  
 basic life support (BLS), 248  
   algorithm, 148  
   flow chart, 149  
 'bats wings', 118  
 beta-adrenoceptor antagonists, 206  
 beta blockers, 12, 27, 30, 127, 141, 142, 206, 207, 208, 227, 237, 263–4, 290  
 Bezold–Jarisch reflex, 10  
 bicuspid valve, 2  
 bifascicular block, 90  
 biguanides, 32  
 bi-level positive airway pressure (BiPAP) ventilation, 261  
 biochemical markers, of myocardial necrosis, 112  
 bipolar leads, 84  
 bleeding, 123  
 blood glucose level (BGL), 31  
 blood pressure (BP), 29  
   assessment  
     auscultatory method, 73  
     automated devices, 73  
     palpatory method, 73  
   classification, 30  
   control, 286  
   follow-up, 30  
   measuring, 29  
 blood tests, 109  
 blood urea nitrogen (BUN), 110  
 body mass index (BMI), 32, 33  
 bradyarrhythmia, 140, 227  
   treatment, 239–40  
 broad-complex tachycardia, treatment of, 240  
 Bruce Protocol, 126  
 Bruce, Robert A., 126  
 Brugada syndrome, 141–2  
 bundle branch block, 88–91  
 bupropion, 287  
 'butterfly effect', 118  
 bystander CPR, 146
- C natriuretic peptide, 12  
 C-reactive protein (CRP), 114, 163
- caffeinated beverage, 129  
 calcium antagonists, 209, 237  
   in acute coronary syndromes (ACSs), 209  
 calcium channel blockers, 30, 127, 207, 208  
 capillaries, 24  
 cardiac and vascular function, regulation of  
   baroreceptors, 10  
   chemoreceptors, 10–11  
   CNS regulation, 8–9  
   electrolytes, 13  
   humoral control, 11–13  
   vasomotor control, 9  
 cardiac arrest  
   and BLS, 147–9  
   definition, 244  
 cardiac arrhythmia, *see* arrhythmia  
 cardiac auscultation, 74–6  
 cardiac axis, 85–6  
 cardiac care units (CCUs), 179, 182–3  
 cardiac catheterisation, 118  
   benefit and risks associated with, 121  
   intra-procedural complications, 122  
   patient preparation, 119–20  
   peri-procedural considerations, 121–2  
   post-procedural care, 122  
   post-procedural complication, 123  
   safety, 120  
 cardiac cells, 15–16  
 cardiac conduction system, 18–20  
 cardiac cycle, 2, 4  
   atrial systole, 3–5  
   isovolumetric contraction, 5  
   isovolumetric relaxation, 6  
   rapid ejection, 5  
   rapid filling, 6  
   reduced ejection, 5  
   reduced filling, 6  
 cardiac electrophysiology, 15  
   action potential, 16  
   in non-pacemaker cells, 17–18  
   cardiac cells, 15–16  
   cardiac conduction system, 18–20  
   electrocardiogram, 20  
 cardiac glycosides, 263  
 cardiac markers, in ACS, 174  
 cardiac monitoring systems, 99, 225  
   arrhythmia monitoring, indications for, 103, 104  
   ECG monitoring systems and lead formats, 100  
     ambulatory ECG, 103  
     derived 12-lead ECG monitoring systems, 102  
     five-electrode monitoring systems, 101  
     telemetry monitoring systems, 102–3  
     three-electrode monitoring systems, 100–101  
     twelve-lead (10 electrode) monitoring systems, 101–2  
   new generation, 102  
   nursing considerations, in care of patient with ECG monitoring, 103, 105–7

- cardiac MRI, 130
- cardiac natriuretic peptides, 112, 113–14
- cardiac output, 6–7
  - physiological changes, 10
- cardiac pacing, 239
- cardiac rehabilitation (CR), 274
  - clearance, 110
- cardiac resynchronisation therapy (CRT), 265
- Cardiac Society Australia, 118
- cardiac veins, 21
- cardioacceleratory centre, 9
- cardiomegaly, 117
- cardiomyopathies, and SCD
  - arrhythmogenic right ventricular cardiomyopathy (AVRC), 141
  - dilated cardiomyopathy, 141
  - hypertrophic cardiomyopathy, 141
- cardio-protective drug therapy, 289
  - antiplatelet agents and anticoagulants, 289
    - ACE inhibitors, 289–90
    - angiotensin inhibitors, 290
    - angiotensin receptor blockers (ARBs), 290
      - beta blockers, 290
      - hormone therapy, 290
- cardiopulmonary resuscitation (CPR), 128, 145, 146, 153, 250, 251
- cardiostimulatory centre, 9
- cardiothoracic ratio (CTR), 117
- cardiovascular assessment, 67
  - health history, 67–70
  - physical examination, 70
    - blood pressure, 73
    - cardiac auscultation, 74–6
    - general appearance, 70
    - peripheral vascular system, 72–3
    - precordial inspection and palpation, 70–71
    - pulses, 71–2
    - respiratory assessment, 77–9
- cardiovascular disease (CVD), 39
  - populations at risk, 39
  - relative risk, 40
  - risk assessment tools, 40–41
  - risk factors for, 26, 39–40
    - behavioural risk factors, 32–4
    - biomedical risk factors, 27–32
    - classification, 26–7
    - psychosocial risk factors, 34–5
- cardiovascular system
  - cardiac cycle, 2
    - atrial systole, 3–5
    - isovolumetric contraction, 5
    - isovolumetric relaxation, 6
    - rapid ejection, 5
    - rapid filling, 6
    - reduced ejection, 5
    - reduced filling, 6
  - cardiac output, 6–7
    - heart, anatomy of, 1
    - carotid bodies, 11
    - catecholaminergic polymorphic VT, 238
    - catecholamines, 11
    - central nervous system (CNS)
      - in cardiovascular system regulation, 8–9
    - ‘chain of survival’ approach, 145, 243, 246
    - chamber enlargement, 88
    - chemoreceptors, 10–11
    - chest film, *see* chest X-ray (CXR)
    - chest pain, 125
      - assessment, 68–9
      - diagnosis, 179
    - chest X-ray (CXR), 116, 260
      - AHF diagnosis, 260
      - interpretation, 117
    - chlamydia pneumoniae, 163
    - chordae tendinae, 2
    - chronic care model, 270
    - chronic heart failure, 162
      - managing, 266
    - chronic renal failure, 162
    - cigarette smoke, 34
      - cardiovascular effects, 34
    - CINAHL, 54
    - clinical audit, 56
    - clinical practice guidelines, 54
    - clinical trial, participation in, 62, 63–4
    - clopidogrel, 210, 211–12, 271, 289
    - clotting screen, 112
    - ‘clustering’ of risk factors, 40
    - ‘cold and dry’ patients, 260
    - ‘cold and wet’ patients, 260
    - collateral circulation, 23–4
    - colour flow mapping, 124
    - community first responders (CFRs), 187
    - community health workers, 275
    - complete blood count/picture (CBC/CBP), *see* complete blood examination (CBE)
    - complete blood examination (CBE), 111–12
    - computerised tomography (CT), 123, 132
    - continuous positive airways pressure (CPAP)
      - ventilation, 261
    - contractile cells, 15
    - contractility, meaning of, 7
    - conventional cardiac monitoring, 100
    - Cornell voltage criteria, 88
    - coronary angiography, 118, 132
      - indications for, 119
    - coronary arteries, 21
    - coronary artery disease (CAD), 30, 161, 162, 179
    - coronary bypass graft surgery (CABG), 170
    - coronary care unit (CCU), 102, 270
    - coronary circulation, 22
      - collateral circulation, 23–4
      - coronary venous circulation, 24
      - LAD artery, 23

- LCX artery, 23
- left main coronary artery, 22
- microvascular circulation, 24
- right coronary artery, 23
- coronary flow reserve, 127
- coronary heart disease (CHD), 40, 137, 281
- coronary magnetic resonance angiography (CMRA), 131
- coronary venous circulation, 24
- coalescence, 270
  - acute cardiac event, following 274
  - high-risk groups, 272
  - intervention models, 274
    - community health workers, 275
    - home-based services, 274–5
    - information technology, 275
    - nurse-coordinated clinics, 275
  - nursing strategies, 275–6
  - palliative care, 276
  - patient need, assessment and identification
    - of, 272
  - self-management promotion, 272–3
  - spouses and family members, particular
    - concerns of, 273–4
- creatine kinase (CK), 113, 168
- creatinine, 110, 111
- critical care outreach teams, 248
- critically ill patients, early recognition and
  - management of, 246–8
- CRUSADE, 56
- CVD, risk factors for, 69
- cytomegalovirus, 163
  
- data, meaning of, 188
- Database of Uncertainties about the Effects of Treatments (DUETs), 54
- defibrillation, 147, 149, 250
- Department of Health (2005), 137
- depolarisation, 16, 20
  - and repolarisation, 16, 81–3
- diabetes, 29, 111, 162
  - management, 287
- diabetes mellitus, 31
  - classifications, 31
  - management, 31–2
  - testing, 31
- diagnostic abdominal ultrasound, 123
- diagnostic perfusion imaging, 128
- diagnostic procedures, 116
  - cardiac catheterisation (angiogram), 118
    - patient preparation, 119–20
    - peri-procedural considerations, 121–2
    - post-procedural care, 122
    - post-procedural complication, 123
    - safety, 120
  - cardiomegaly, 117
  - chest X-ray, 116
    - interpretation, 117
  - computerised tomography, 132
  - echocardiography, 124
    - techniques, 125
    - transoesophageal echocardiography, 124–5
    - transthoracic echocardiography, 124
  - electrophysiology studies, 132
    - patient and procedural considerations, 133
  - left ventricular (LV) failure, 117–18
  - magnetic resonance imaging (MRI), 130
    - following device implant, 131–2
    - risks, 130–31
    - types, 131
  - stress testing
    - exercise tolerance test (ETT), 125–8
    - myocardial perfusion imaging, 128–9
    - stress echocardiography, 129–30
- diastole, 2
- diastolic murmurs, 76
- diets, 284–5
- digoxin, 237
- dihydropyridines, 17
- dilated cardiomyopathy (DCM), 141
- diltiazem, 17
- dipeptidyl peptidase IV (DPP-IV), 32
- directed search method, 117
- discharge planning, 280–81
- diuretics, 262
- do-not-resuscitate (DNR) orders, 154
- dobutamine, 263
- domicile (D0), 186–7
- door, meaning of, 187–8
- door-to-balloon times, 189
- door-to-needle time, 186, 187
- dopamine, 263
- Doppler echo, 124
- drug/destination, 189–90
- dyslipidaemia, 28
  
- early warning scoring systems (EWS), 247
- echo, modes of, 124
- echocardiography, 124, 140
  - in acute cardiac care
    - indications for, 125
    - AHF diagnosis, 260
    - techniques, 125
    - transoesophageal echocardiography, 124–5
    - transthoracic echocardiography, 124
- ectopic beats, 227, 228
- effective refractory period, 17
- Einthoven's triangle, 83
- electrocardiogram (ECG) interpretation, 3, 20, 81
  - 12-lead ECG, 94
    - documentation, 96
    - electrodes, attaching, 96
    - equipment preparation, 94–5
    - interpretation, 96
    - obtaining, 96

- electrocardiogram (ECG) interpretation (*continued*)
  - patient preparation, 95
  - quality, 96
- bundle branch block, 88–91
- cardiac axis, determining, 85–6
- chamber enlargement, 88
- depolarisation and repolarisation, normal sequence of, 81–3
- electrocardiography, theoretical basis of, 83–4
- heart rate and electrocardiographic intervals, determination of, 86
  - electrocardiographic waveforms and intervals, 86–7
  - heart rate, 86
  - heart rhythm, 86
- monitoring systems, 99
  - ambulatory ECG, 103
  - derived 12-lead ECG monitoring systems, 102
  - five-electrode monitoring systems, 101 and lead formats, 100
  - nursing considerations in care of patient with, 103, 105–7
  - telemetry monitoring systems, 102–3
  - three-electrode monitoring systems, 100–101
  - twelve-lead (10 electrode) monitoring systems, 101–2
- myocardial ischaemia and infarction, ECG changes related to, 91
  - incremental ECG leads, 93–4
  - infarction, site of, 93
  - myocardial infarction, 91
  - Q waves, 93
  - ST segment, 92–3
  - sub-endocardial ischaemia, 91
  - sub-epicardial or transmural ischaemia, 91
  - T-wave abnormalities, 93
- electrocardiography, 81
  - AHF diagnosis, 260
  - theoretical basis, 83–4
  - waveforms and intervals, 82, 86–7
- electrodes, 96
- electrolytes, 13, 110
- electromechanical dissociation, 140
- electron-beam computed tomography (EBCT), 132
- electrophysiology study (EPS), 132
  - patient and procedural considerations, 133
- Emergency Medical Services (EMS), 146
- EMMACE, 181
- end diastolic volume (EDV), 3
- end-of-life care issues, 153, 155
- end-stage renal failure (ESRD), 32
- end-systolic volume (ESV), 5
- endocarditis, 112
- endocardium, 2
- endothelial dysfunction, 162
- endotracheal intubation, 157
- enhanced automaticity, 224
- enoxaparine, 213
- epicardial arteries, 21
- epicardium, 2
- epinephrine, 11, 263
- escape beats, 228, 232
- estimated glomerular filtration rate (eGFR), 110, 111
- ethical dilemma, 62
- ethics of research, in acute cardiac care, 59
  - clinical trial, participation in, 63–4
  - ethical dilemma, 62
  - evidence-based medicine and clinical trials, 60
  - genetic research, 63
  - new pharmaceutical agents marketing and pricing, ethical issues in, 64
  - trial participation, informed consent for, 60–2
- ethnic populations, CVD risks for, 43
- European Society of Cardiology (ESC), 180
- European Systemic Coronary Risk Estimation (SCORE), 40, 41
- evidence-based medicine and clinical trials, 60
  - definition, 52, 60
- evidence-based practice (EBP), 50
  - barriers, 56–7
  - need for change, 50–1
  - process, 52–6
- exercise stress test (EST), 125
  - contraindications for, 127
  - diagnostic and prognostic indicators for, 126
- exercise tolerance test (ETT), 125–8, 180, 181
  - interpretation, 127
  - safety, 127–8
- exercise training, and physical activity counselling, 288–9
- ezetimibe, 29
- fasting blood glucose (FBG), 31
- fats, 28
- fibrates, 285
- fibrinolytic therapy, 195–6
  - nursing considerations in, 196–7
- fibrous pericardium, 2
- first-degree heart block, 227, 229, 230
- First Medical Contact, 188
- first responders, guidelines for, 249–50
- five-electrode monitoring systems, 101
- flecainide, 142
- flutter waves, 236
- foam cells, 162
- Framingham risk equations, 41
- friction rub, 76
- full blood examination/count (FBE/FBC), *see* complete blood examination (CBE)
- futility, in resuscitation, 153
- gadoflourine, 131
- generic laboratory tests, 109–10

- genetic research, 63  
genetic syndromes, and SCD  
  Brugada syndrome, 141–2  
  long QT syndrome, 142–3  
geographical variations, coronary heart disease in, 44  
gestational diabetes, 31  
glucose measurement, 111  
glyceryl trinitrate (GTN), *see* nitroglycerin (NTG)  
glycosylated haemoglobin (HbA1c), 287  
‘gold standard’ investigation, 140  
golden hour, 185  
GRACE, 181  
gradient-echo imaging, 131  
Gray, Henry, 1  
GUSTO ECG criteria, 92  
GUSTO-1, 181
- health information, volume of, 51  
Health Survey for England (2003), 282  
heart  
  basic anatomy, 1, 3  
  block, 227  
    atrioventricular dissociation, 232  
    first-degree AV block, 227, 229, 230  
    second-degree AV block, 229, 230  
    third-degree/‘complete’ heart block, 230, 231  
  failure, 125  
  murmurs, 75–6  
  rhythm, 86  
  sounds, 75–6  
Heart Outcomes Prevention Evaluation (HOPE)  
  trial (2000), 289  
heart rate, 86  
  and electrocardiographic intervals, 86–7  
Heart Rhythm Society (HRS), 133  
Heberden, William, 167  
help-seeking behaviour, delays in, 186, 187  
hexaxial reference system, 84, 85  
high-density lipid (HDL) cholesterol, 111, 285  
Holter monitoring, 103  
home-based services, for cardiac rehabilitation, 275  
hormone therapy, 290  
humoral control, 11–13  
hypertension, 29, 162  
hypertrophic cardiomyopathy (HCM), 139, 141  
hypothalamic-pituitary-adrenal axis (HPA axis), 35
- idioventricular rhythm (IVR), 232  
imaging, 129  
impaired fasting glucose (IFG), 31  
impaired glucose tolerance (IGT), 31  
implantable cardioverter defibrillators (ICDs), 141, 156–7, 273  
incremental ECG leads, 93–4  
  posterior leads, 93  
  right ventricular leads, 93  
infarction, site of, 93
- information technology, 275  
informed consent  
  elements, 60  
  for trial participation, 60–2  
in-hospital cardiac arrest, initial management of, 249  
in-hospital resuscitation, 243–4, 248  
  audit and data collection, 253  
  basic life support (BLS), 248  
  cardiac arrest, systems for identifying patients at risk of, 245–6  
  critically ill patients, early recognition and management of, 246–8  
  early cardiopulmonary resuscitation and defibrillation, 250  
  first responders, guidelines for, 249–50  
  scope of practice, 250  
    advanced care directives, 252–3  
    advanced life support, 250–1  
    equipment, 251  
    post-resuscitation care, 251–2  
    team activation, 248–9  
ino/chronotropic adrenergic agents, 129  
inotropic agents, 263  
intotropy, 7  
insulin, 111  
integrated outreach programs, 247  
intensive care liaison nurses, 247, 248  
International Liaison Committee on Resuscitation (ILCOR), 253  
international normalised ratio (INR), 112  
internet, 51  
intra-aortic balloon pump (IABP), 264  
intra-plaque haemorrhage, 163  
intravenous NTG (IV NTG), 205  
isoelectric PR interval, 82  
isovolumetric contraction, 5  
isovolumetric relaxation, 6
- Jervell Lange-Nielsen syndrome, 142  
Joint British Coronary Risk Prediction Charts, 41  
Joint British Societies (JBS), 5, 41  
jugular venous pressure (JVP), 3, 71–2  
junctional rhythm, 232, 235
- Kerley B lines, 118
- L-type calcium channels, 17  
laboratory tests, 109  
  for AHF diagnosis, 261  
  biochemical markers, 112  
  C-reactive protein (CRP), 114  
  cardiac natriuretic peptides, 113–14  
  clotting screen, 112  
  complete blood examination (CBE), 111–12  
  electrolytes, 110  
  generic laboratory tests, 109–10  
  glucose measurement, 111

- laboratory tests (*continued*)
- lipid profiles, 111
  - myocardial necrosis, markers of, 112–13
  - renal function, 110–11
- latent pacemakers, 224
- left anterior descending (LAD), 22
- left anterior fascicular block (LAFB), 90
- left anterior hemi-block (LAHB), 90
- left atrial enlargement (LAE), 88
- left atrium (LA), 2
- left axis deviation (LAD), 85
- left bundle branch block (LBBB), 89, 90
- left circumflex (LCX/CX), 22
- left main coronary artery (LMCA/LMA), 22
- left posterior fascicular block (LPFB), 90
- left posterior hemi-block (LPHB), 90
- left ventricle (LV), 2
- dysfunction, 137
  - failure, 117–18
- left ventricular ejection fraction (LVEF), 5
- left ventricular end diastolic pressure (LVEDP), 3
- left ventricular hypertrophy (LVH), 88
- levosimendan, 263
- limb leads, 96
- lipid management, 285–6
- lipid profiles, 111
- lipids, 28
- long QT syndrome (LQTS), 138, 142–3
- low-density lipid (LDL) cholesterol, 111, 162, 285
- low-dose thiazide diuretics, 30
- low-molecular-weight heparins (LMWH), 212–13
- in acute coronary syndrome (ACS), 213
  - in nursing management, 214
- low socioeconomic populations, CVD risks for, 44
- lytic therapy, 195–7
- magnetic resonance imaging (MRI), 130, 181
- following implanted device, 131–2
  - risks, 130–31
  - scanner unit, 130
  - types, 131
- manual defibrillation, 250
- Mason–Likar configuration, 101
- maximum predicted heart rate (MPHR), 126
- mechanical reperfusion, 197
- Medical Emergency Teams (MET), 243, 247
- MEDLINE, 54
- medulla oblongata, 9
- mercury sphygmomanometer, 29
- meta-analysis, 53–4
- microalbuminuria, 32
- microvascular circulation, 24
- mitral valve, 2
- Mobitz type I heart block, 230
- Mobitz type II heart block, 230
- modified chest lead (MCL), 100
- monounsaturated fat, 28
- morphine, 262, 263
- motion/M-mode echo, 124
- multidetector row computed tomography (MDCT), 132
- multifocal atrial tachycardia (MAT), 234, 235
- 'multislice' CT scanning, 132
- myocardial abnormalities, 132
- myocardial infarction (MI), 7, 91, 118
- and myocardial ischaemia, 7, 91
    - incremental ECG leads, 93–4
    - infarction, site of, 93
    - myocardial infarction (MI), 91
    - Q waves, 93
    - ST segment, 92–3
    - sub-endocardial ischaemia, 91
    - sub-epicardial ischaemia, 91
    - symptoms, 171–2
    - T-wave abnormalities, 93, 94
- myocardial necrosis, markers of, 112–13
- myocardial oxygen consumption (MVO<sub>2</sub>), 7
- myocardial perfusion imaging, 128–9
- patient preparation, 129
  - safety, 129
- myocardium, 2
- myocytes, 16
- myoglobin, 180
- N-acetylcysteine (NAC), 205
- narrow complex tachycardia (NCT), 233
- treatment of, 240–41
- National Heart Attack Alert Program (NHAAP)
- Co-ordinating Committee, 186
- National Heart Foundation of Australia, 274
- National Institute for Health and Clinical Excellence (NICE), 45, 56
- National Institute of Clinical Studies (NICS), 56
- National Service Framework, 56
- negative chronotropy, 9
- negative dromotropy, 9
- negative inotropy, 9
- nesiritide, 263
- new pharmaceutical agents marketing and pricing, ethical issues in, 64
- New Zealand Acute Coronary Syndrome Guidelines Working Group, 118
- New Zealand Cardiovascular Risk Calculator, 41
- New Zealand Guidelines Group, 46
- niacin, *see* nicotinic acid
- nicotine replacement therapy (NRT), 34, 287
- nicotinic acid, 285
- nifedipine, 17, 209
- nitrates, 205, 263
- tolerance, 205
  - usage, evidence for, 205–6
- nitroglycerin (NTG), 205
- non-invasive monitoring systems, 260
- non-invasive pacing, 239
- non-invasive positive pressure ventilation (NIPPV), 261–2



- non-nicotine replacement therapies, 287
- non-pacemaker cells, 16
  - action potential in, 17–18
- non-Q wave acute MI (NQAMI), 91
- non-sinus atrial rhythms, 227, 234
- non-ST elevation acute coronary syndrome (NSTE-ACS), 118, 170
- non-ST elevation myocardial infarction (NSTEMI), 169, 179, 206
- non-thrombolytic pharmacotherapy, 194–5
- norepinephrine, 11, 263
- normal sinus rhythm (NSR), 223
- normal waveforms, and electrocardiographic intervals, 87
- nurse-coordinated clinics, 275
- nursing strategies, to promote convalescence, 275–6
- nutritional counseling, 284–5
  
- obtuse marginal (OM), 23
- oestrogen, 290
- opiates, 262–3
- oral glucose tolerance test (OGTT), 31
- organ donation, 157
- osmoreceptors, 8
- out-of-hospital cardiac arrest (OHCA), 145, 146
  - and automated external defibrillation (AED), 149
    - factors affecting defibrillation, 149–50
  - cardiac arrest and BLS, recognition of, 147–9
    - victim and rescuer, hazards to, 146
      - delay, 147
      - environmental hazards, 147
      - hazards associated with treatment, 147
      - patient/bystander hazards, 147
      - rescuer, risks to, 146
      - resource issues, 147
      - scene safety, 146
- overweight/obesity, 32
  - management, 33
  - measuring, 32–3
- oxygenation, 261
  - non-invasive positive pres-sure ventilation (NIPPV), 261–2
  
- P wave, 18, 82, 88
- pain relief, 188
- palliative care, 276
- palpation, 70–71
- palpatory method, 73
- papillary muscles, 2
- parasympathetic innervation, 9
- paroxysmal atrial tachycardia (PAT), 234, 235
- ‘patient at-risk’ teams (PART), 247
- patient perceptions, of resuscitation, 154
- percussion (fist) pacing, 239
- percutaneous coronary intervention (PCI), 170, 197, 201
  - failure, 200
  - as primary therapy, 198–9
- percutaneous transluminal coronary angioplasty (PTCA), 119
- pericardial fluid, 2
- pericarditis, 92
- pericardium, 2
- peripheral artery disease, 162
- peripheral vascular system assessment, 72–3
- pharmacologic agents, for evaluation of myocardial perfusion, 129
- pharmacologic stress echocardiography, 130
- pharmacotherapy, for AHF
  - diuretics, 262
  - opiates, 262–3
- phosphodiesterase inhibitors, 263
- physical activity counseling, and exercise training, 288–9
- physical inactivity, 34
- PICO format, 52–3
- plaque disruption, 162–3
- platelet GP IIb/IIIa receptor antagonists, 213
  - in acute coronary syndrome (ACS), 213
  - in nursing management, 215
- pneumonia, 112
- point-of-care device method, 111
- point of care testing, 180
- polyunsaturated fat, 28
- populations at risk, 39
  - advancing age, 42
    - CVD, risk factors for, 39–40
  - ethnic groups, 43
  - evidence-based therapies, 46
  - geographical population distributions, 44
  - individuals with poor psychosocial health, 44–5
  - low socioeconomic populations, 44
  - people with a high incidence of significant risk factors, 42
  - people with a strong family history, 42
  - people with established CVD, 42
  - risk assessment tools, 40–1
  - risk clarification, 40
  - treatment guidelines, 45–6
  - women, 42–3
- Position and Mobilisation Post-Angiography Study (PAMPAS), 124
- positive chronotropy, 9
- positive dromotropy, 9
- positive inotropic agents, 263
- positive inotropy, 9
- posterior descending artery (PDA), 23
- posterior leads, 93
- posterolateral artery (PLA), 23
- post-menopausal hormone therapy, 290
- post-resuscitation care, 251–2
- PQRST mnemonic, 68–9
- prasugrel, 211–12
- precordial inspection, 70
- precordial leads, 84, 96
- pre-diabetes, 31
- pre-hospital thrombolysis, 189

- preload, 6
- pressor, 9
- 'presumed consent', 157
- primary percutaneous coronary intervention (PPCI), 186, 188, 189
- procainamide, 142
- progesterone, 290
- proxy consent, 61–2
- pseudoaneurysm, 123
- psychosocial interventions, 288
- pulmonary circulation, 2
- pulmonary venous congestion, 117, 118
- pulse oximetry, 79
- pulseless electrical activity (PEA), 140, 146
- pulseless VT, 146
- pulses assessment, 71–2
- Purkinje fibres, 19
- PURSUIT, 181
  
- Q wave acute MI (QAMI), 91
- Q waves, 93
- QRS complex, 19, 174
  - components, 19
  
- radiographic/fluoroscopic systems, 120
- radionuclide stress testing, 128, 129
- randomised controlled trials (RCTs), 54
- Rapid Early Action for Coronary Treatment (REACT)
  - community trial, 187
- refractory AHF, 264
  - cardiac resynchronisation therapy, 265–6
  - intra-aortic balloon pump (IABP), 264
  - ventricular assist devices, 264–5
- regain return of spontaneous circulation (ROSC), 251
- regular/irregular heart rhythms, 226
- relative risk, 40
- renal failure, 32
- renal function, 110–11
  - and normal reference ranges, 111
- renin-angiotensin-aldosterone system (RAAS), 11, 13
- re-occlusion, preventing and detecting, 200–201
- reperfusion, benefits of, 185–6
- reperfusion strategies, 193
  - failure, detecting and managing
    - failed PCI, 200
    - failed thrombolysis, 199–200
  - options for
    - appropriate reperfusion strategy, choosing, 197–9
    - fibrinolysis/thrombolysis, 195–7
    - mechanical reperfusion, 197
    - non-thrombolytic pharmacotherapy, 194–5
  - principles, 194
  - re-occlusion, preventing and detecting, 200–1
  
- STEMI, pathogenesis of, 193–4
  - treatment time delays reduction, 199
  
- repolarisation, 16, 81–3
- 'rescue chain' model, 246
- research, quality of, 51
- respiratory assessment, 77–9
- responders, guidelines for, 249–50
- resuscitation, ethical issues in, 152
  - DNR conversation, 154
  - futility, 153
  - guiding ethical principles, 152–3
  - newly dead persons, for training and research, 157
  - organ donation, 157
  - patient perceptions, 154
  - rights of individual versus needs of society, 153–4
  - withdraw life-sustaining treatment, 156
    - employment of medical devices, to preserve life, 156
    - quality of life issues with ICD, 156–7
  - witnessed resuscitation, 154
    - advanced directive, 155–6
  
- retroperitoneal bleeding, 123
- 'reversible defect', 128
- Reynolds Risk Score, 41
- right atrial enlargement (RAE), 88
- right atrium (RA), 2
- right axis deviation, 85
- right bundle branch block (RBBB), 88, 89, 141
- right coronary artery (RCA), 23
- right ventricle (RV), 2
- right ventricular end diastolic pressure (RVEDP), 3
- right ventricular hypertrophy (RVH), 88
- right ventricular leads, 93
- risk assessment tools, 40–1
- risk factor management
  - blood pressure control, 286
  - diabetes management, 287
  - lipid management, 285–6
  - smoking cessation, 287–8
  - weight management, 286–7
- risk scoring systems, for ACS patients, 181–2
- risk stratification
  - in acute coronary syndromes (ACSs), 178, 179
    - chest pain units (CPUs), 182–3
    - guidelines, 180–1
    - risk scores, 181–2
- Romano–Ward and Timothy syndromes, 142
- sarcomeres, 16
- saturated fat, 28
- second-degree heart block, 229, 230
- secondary prevention, 281
  - cardio-protective drug therapy, 289
    - ACE inhibitors, 289–90
    - angiotensin inhibitors, 290
    - angiotensin receptor blockers (ARBs), 290
    - antiplatelet agents and anticoagulants, 289
    - beta blockers, 290
    - hormone therapy, 290
  - challenges in, 290–1

- components, 283
    - nutritional counseling, 284–5
    - patient assessment, 284
    - physical activity counselling and exercise training, 288–9
    - psychosocial interventions, 288
    - risk factor management, 285–8
  - effectiveness, 282
  - provision, 282–3
  - target population, 282
  - self-care, 273
  - self-management, 273
  - septal depolarization, 82
  - serous pericardium, 2
  - serum creatinine level, 32
  - silent ischaemia, 172
  - Simple Risk Index, 181
  - single-photon emission computed tomography (SPECT), 128–9
  - sinus bradycardia, 18, 227
  - sinus rhythms, 223
  - sinus tachycardia, 18, 232–3
  - smoking cessation, 287–8
  - sodium nitroprusside, 263
  - spectral Doppler, 124
  - spin-echo imaging, 131
  - spironalactone, 216
  - ST depression, 92
  - ST elevation acute coronary syndrome (STE-ACS), 170
  - ST-elevation myocardial infarction (STEMI), 169, 179, 186, 193, 260
    - lytic therapy, 196
    - pathogenesis, 193–4
  - ST-segment, 92–3
  - stable angina, 168
  - standard 12-lead ECG, 101
  - Starling's Law, 7
  - statin therapy, 28
  - statins, 216, 285
  - 'sternal notch', 96
  - stethoscope, 74
  - stress echocardiography, 125, 129–30, 181
  - stress scintigraphy, 181
  - stress testing
    - exercise tolerance test (ETT), 125–8
    - myocardial perfusion imaging, 128–9
    - stress echocardiography, 129–30
  - stroke volume, 5
  - sub-endocardial ischaemia, 91
  - sub-epicardial arteries, 21
  - sub-epicardial ischaemia, 91
  - subsidiary pacemakers, 224
  - sudden cardiac death (SCD), 137
    - burden of disease and risk factors for, 138–9
    - and cardiomyopathies
      - arrhythmogenic right ventricular cardiomyopathy (AVRC), 141
      - dilated cardiomyopathy, 141
      - hypertrophic cardiomyopathy, 141
  - definitions, 138
  - and genetic syndromes
    - Brugada syndrome, 141–2
    - long QT syndrome, 142–3
  - interplay of risk factors for, 139
  - risk factor for, 137
  - structural abnormalities, 140
    - arrhythmias, 140
    - sudden death, in young, 139–40
  - sulfonylureas, 32
  - summation gallop, 75
  - supraventricular tachycardia (SVT), 233–4, 235
  - sympathetic innervation, 9
  - synchronised DC cardioversion, 240
  - systematic review, 53–4
  - systemic circulation, 2
  - systemic vascular resistance (SVR), 9, 12
  - systole, 2
  - systolic murmurs, 75–6
- 
- T waves, 91, 92, 173
    - abnormalities, 93, 94
  - tachyarrhythmias, treatment of, 240–41
  - tachycardias, 232
    - atrial fibrillation, 234, 236
    - atrial flutter, 236–7
    - sinus tachycardia, 232–3
    - supraventricular tachycardia (SVT), 233–4, 235
    - ventricular fibrillation, 238
    - ventricular tachycardia (VT), 237–8
  - team activation, in in-hospital resuscitation, 248–9
  - telemetry
    - meaning, 102
    - monitoring systems, 102–3
  - terminal lymphatic vessels, 24
  - thallium 201, 129
  - thespian veins, 24
  - thiazolidinediones, 32
  - third-degree (complete) heart block, 230, 231
  - three-electrode monitoring systems, 100–1
  - thrombolysis, 188
    - therapy, 195–6
    - failure, 199–200
    - nursing considerations in, 196–7
  - thrombosis, in ACS, 164
  - time to treatment
    - delays, identifying and addressing, 186–90
    - early reperfusion, benefits of, 185–6
  - TIMI, 181, 182
  - tobacco use, 33
  - tomographic myocardial perfusion data, orientation for
    - display of, 128
  - torsades de pointes, 238
  - total cholesterol/HDL ratio, 111
  - 'tracers', 128

- trans fat, 28
- transcutaneous pacing, 239
- transmural ischaemia, *see* sub-epicardial ischaemia
- transoesophageal echocardiography (TOE), 124–5
- transthoracic echo (TTE), 124
- transthoracic echocardiography, 124
- transthoracic impedance, 149
- transvenous pacing, 239
- tricuspid valve, 2
- trifascicular block, 90
- triglycerides, 111, 285
- tropomyosin, 16
- troponin (Tn), 168
  - testing, 113
- troponin-C (TN-C), 16
- troponin-I (cTnI), 16, 113
- troponin-T (cTnT), 16, 113
- troponins (cTnT/cTnI), 180, 181
- twelve-lead (10 electrode) monitoring systems, 101–2
- two-dimensional (2D) or ‘cross sectional’ echo, 124
- type 1 diabetes, 31
- type 2 diabetes, 29, 31
  
- ‘undifferentiated chest pain’, 179
- unfractionated heparin (UFH), in ACS, 212
  - in nursing management, 214
- United Kingdom Heart Attack Study (UKHAS), 186
- United Kingdom Prospective Diabetes Study (UKPDS-35), 41, 287
- unstable angina, 168, 179
- unstable angina pectoris (UAP), 169, 206
- upper lobe diversion/congestion, 117
- urea, 110, 111
- Utstein guidelines, 253
  
- varenicilin, 287
- vasoconstriction, 164
  
- vasodilators, 129, 263
  - beta-adrenergic blockers, 263–4
    - as first-line therapy, 263
    - positive inotropic agents, 263
- vasomotor control, 9
- ventricular assist devices, 264–5
- ventricular fibrillation (VF), 140, 146, 149, 238
- ventricular filling, 5
- ventricular rate, 226
- ventricular tachycardia (VT), 140, 237–8
- venules, 24
- verapamil, 17
- victim and rescuer, hazards to, 146
  - delay, 147
  - environmental hazards, 147
  - hazards associated with treatment, 147
  - patient/bystander hazards, 147
  - rescuer, risks to, 146
  - resource issues, 147
  - scene safety, 146
- volume receptors, 8
- vulnerable plaque, 163
  
- Wagner, 270
- wandering atrial pacemaker, 227, 234
- warfarin, 188, 289
- ‘warm and dry’ patients, 259–60
- ‘warm and wet’ patients, 260
- weight management, 286–7
- Wenckebach, *see* Mobitz type I heart block
- witnessed resuscitation, 154
  - advanced directive, 155–6
- women, CVD risks for, 42–3
- World Health Organization (WHO), 138, 271
  
- zero potential, 83–4